Top medical innovations for 2019

The utilization of artificial intelligence (AI) in healthcare was named the second most important medical innovation for 2019 by the Cleveland Clinic, marking a big rise in the emerging technology.

Cleveland Clinic physicians and scientists expect AI to be a game changer in the healthcare industry in 2019 because of its potential to help doctors with decision support, image analysis and patient triage, according to the clinic’s ranking of the top medical innovations for 2019. Top of the list is finding alternative therapy to combat the opioid crisis, which reached new heights last year. 

“Today, artificial intelligence is helping physicians make smarter decisions at the point of care, improving the ease and accuracy of viewing patient scans and reducing physician burnout,” the ranking reads. “With AI’s continued integration into healthcare, caring for patients has become a matter of working smarter, not harder.”

AI was not mentioned on Cleveland Clinic's 2018 or 2017 lists.  

The full list—ranked by importance—includes:

  1. Alternative therapy for pain in the fight against opioids
  2. The advent of AI in healthcare
  3. Expanded window for acute stroke intervention
  4. Advanced in immunotherapy for cancer treatment
  5. Patient-specific products achieved with 3D printing
  6. Virtual and mixed reality for medical education
  7. Visor for prehospital stroke diagnosis
  8. Innovation in robotic surgery
  9. Mitral and tricuspid valve percutaneous replacement and repair
  10. RNA-based therapies

The Cleveland Clinic announced its Top 10 Medical Innovations of 2019 during a presentation on Wednesday, Oct. 24, at the 2018 Medical Innovation Summit. The list ranks the top innovations expected to have the most significant impact in healthcare in the coming year. It’s selected by a panel of Cleveland Clinic physicians and scientists.

""

Danielle covers Clinical Innovation & Technology as a senior news writer for TriMed Media. Previously, she worked as a news reporter in northeast Missouri and earned a journalism degree from the University of Illinois at Urbana-Champaign. She's also a huge fan of the Chicago Cubs, Bears and Bulls. 

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup